Triazole agonists of the APJ receptor

US10221162B2 · kind B2 · utility

Assignee

• AMGEN INC. · US

Inventors

• Ning Chen · Thousand Oaks, US
• Xiaoqi Chen · Palo Alto, US
• Yinhong Chen · Hayward, US
• Alan C. Cheng · Cambridge, US
• Richard V. Connors · Mesa, US
• Jeffrey Deignan · San Francisco, US
• Paul John Dransfield · Arlington, US
• Xiaohui Du · Foster City, US
• Zice Fu · Foster City, US
• Julie Anne Heath · Chico, US
• Daniel B. Horne · Natick, US
• Jonathan Houze · Cambridge, US
• Matthew R. Kaller · Ventura, US
• Aarif Yusuf Khakoo · Woodside, US
• David John Kopecky · West Hollywood, US
• Su-Jen Lai · Somerville, US
• Zhihua Ma · Lexington, US
• Lawrence R. McGee · Pacifica, US
• Julio C. Medina · Redwood City, US
• Jeffrey T. Mihalic · San Francisco, US
• Nobuko Nishimura · Calabasas, US
• Steven H. Olson · Millbrae, US
• Vatee Pattaropong · Bedford, US
• Gayathri Swaminath · Brisbane, US
• Xiaodong Wang · Zhejiang, CN
• Kevin Yang · San Gabriel, US
• Wen-Chen YEH · Belmont, US
• Mikkel V. Debenedetto · Shrewsbury, US
• Robert P. Farrell · Thousand Oaks, US
• Simon J. Hedley · Thousand Oaks, US

Key dates

• Filing date: Jul 12, 2018
• Grant date: Mar 5, 2019
• Expiry date: Jul 12, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/07
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.